share_log

Milestone Scientific Announces Commercial Rollout of CompuFlo Epidural System at Advanced Spine and Pain Management Following Successful Pilot With Dr. Varinder Dhillon

Milestone Scientific Announces Commercial Rollout of CompuFlo Epidural System at Advanced Spine and Pain Management Following Successful Pilot With Dr. Varinder Dhillon

Milestone Scientific 宣佈在愛文思控股下的脊柱與疼痛管理中心推出 Compuflo 硬膜外系統,這是在與 Varinder Dhillon 醫生成功試點後進行的商業推廣。
GlobeNewswire ·  01/23 16:00

Reports Expanding Adoption of CompuFlo Epidural System Following Previously Announced Medicare Price Assignment

報道顯示,繼之前宣佈的醫療保險價格分配後,CompuFlo硬膜外系統的採用正在擴大。

ROSELAND, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the commercial rollout of its CompuFlo Epidural System at Advanced Spine and Pain Management, LLC, a premier pain management clinic. This rollout follows a successful pilot program conducted with Dr. Varinder Dhillon, whose expertise and feedback validate the clinical benefits of the CompuFlo Epidural System in enhancing patient safety and procedural efficiency.

新澤西州羅塞蘭,2025年1月23日(GLOBE NEWSWIRE)-- Milestone Scientific Inc.(紐交所:MLSS)是一家領先的計算機藥物輸送儀器開發商,提供無痛和精確的注射,今天宣佈在先進脊柱與疼痛管理有限公司進行CompuFlo硬膜外系統的商業推廣,這是一個頂級的疼痛管理診所。這一推廣是在與Varinder Dhillon博士成功的試點項目後進行的,他的專業知識和反饋驗證了CompuFlo硬膜外系統在提高患者安全性和程序效率方面的臨牀益處。

Advanced Spine and Pain Management operates out of SurgiCore Montvale, one of 12 SurgiCore centers located in the New York/New Jersey metropolitan area, highlighting the opportunity for further expansion within the SurgiCore network. In addition, the Company reports increasing adoption of the CompuFlo Epidural System following the previously announced Medicare price assignment, reflecting its clinical and economic benefits.

先進脊柱與疼痛管理公司位於SurgiCore Montvale,這是位於紐約/新澤西大都會區的12個SurgiCore中心之一,突顯了在SurgiCore網絡內進一步擴展的機會。此外,公司報告稱,繼先前宣佈的醫療保險價格分配後,CompuFlo硬膜外系統的採用率正在增加,反映出其臨牀和經濟效益。

The CompuFlo Epidural System, utilizing Milestone Scientific's patented Dynamic Pressure Sensing Technology, provides real-time feedback to confirm accurate needle placement during epidural procedures. This innovative technology significantly reduces the risk of complications associated with traditional techniques, enhancing both patient safety and procedural efficiency.

CompuFlo硬膜外系統採用Milestone Scientific的專利動態壓力感應科技,提供實時反饋以確認硬膜外程序中針頭放置的準確性。這項創新科技顯著降低了與傳統技術相關的併發症風險,提高了患者安全性和操作效率。

Dr. Dhillon commented, "The CompuFlo Epidural System has transformed the way we approach epidural procedures. The technology's precision and reliability enable us to deliver safer and more comfortable care to our patients, while also improving procedural efficiency. I am thrilled integrate it into my workflow at Advanced Spine and Pain Management, and am confident it will continue to deliver outstanding results."

Dhillon博士評論道:「CompuFlo硬膜外系統改變了我們對待硬膜外程序的方式。這項技術的精確和可靠性使我們能夠爲患者提供更安全、更舒適的護理,同時改善操作效率。我很高興將其整合到我在先進脊柱與疼痛管理的工作流程中,並且相信這將繼續帶來卓越的效果。」

Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, stated, "The adoption of the CompuFlo Epidural System by Dr. Dhillon at Advanced Spine and Pain Management illustrates our traction within the healthcare community. With the recent Medicare price assignment, we are witnessing increased adoption of the CompuFlo Epidural System across pain management clinics and other healthcare facilities nationwide."

Milestone Scientific的董事長兼臨時首席執行官Neal Goldman表示:"Dhillon醫生在愛文思控股的脊柱與疼痛管理中心採用CompuFlo硬膜外系統,展示了我們在醫療社區中的影響力。隨着最近醫療保險價格的分配,我們正在見證CompuFlo硬膜外系統在全國的疼痛管理診所和其他醫療機構的廣泛採用。"

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific's computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

關於Milestone Scientific公司。
Milestone Scientific公司(MLSS)是一家專注於科技的醫療研究與開發公司,專利、設計並開發用於醫療和牙科應用的創新注射技術和儀器。Milestone Scientific的計算機控制系統旨在使注射精確、有效,並增加患者的整體舒適度和安全性。他們的專有DPS動態壓力傳感技術儀器是推動下一代設備發展的平台,能夠調節流速並監測從針尖到皮下藥物傳遞平台延伸的壓力,包括局部麻醉藥。欲了解更多信息,請查看MLSS品牌視頻或訪問milestonescientific.com。

Safe Harbor Statement

安全港聲明

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

聯繫:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
電話:212-671-1020


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 209

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。